The overall goal of this project is to develop a biologic therapeutic to treat systemic inflammatory response syndrome (SIRS) using a novel human recombinant lactoferrin that contains """"""""humanized"""""""" glycosylation patterns. SIRS is a clinical expression of the action of complex acute-phase intrinsic mediators that precedes sepsis and subsequent tissue damage leading to Multiple Organ Failure. During sepsis, immune homeostasis is lost leading to destructive immunopathology. This proposal will examine lactoferrin's effects to mediate cellular responses during the development of Lipopolysaccharide (LPS)-induced endotoxemia and live bacteria induced systemic inflammation in mice. The molecular events associated with lactoferrin mediation of monocytic responses that lead to inflammation and oxidative stress will be investigated. The overall hypothesis on this project is that lactoferrin protects against the progression of insult-induced inflammatory responses into septic shock by altering relative amounts of immune mediators and oxidative stressors which exert detrimental effects on gut structure and function. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41GM079810-01
Application #
7217214
Study Section
Special Emphasis Panel (ZRG1-IMM-G (10))
Program Officer
Somers, Scott D
Project Start
2007-05-01
Project End
2008-10-31
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
1
Fiscal Year
2007
Total Cost
$203,739
Indirect Cost
Name
Pharmareview Corporation
Department
Type
DUNS #
133904107
City
Houston
State
TX
Country
United States
Zip Code
77054
Hwang, Shen-An; Kruzel, Marian L; Actor, Jeffrey K (2015) Effects of CHO-expressed recombinant lactoferrins on mouse dendritic cell presentation and function. Innate Immun 21:553-61
O'Shea, Kelly M; Hwang, Shen-An; Actor, Jeffrey K (2015) Immune Activity of BCG Infected Mouse Macrophages Treated with a Novel Recombinant Mouse Lactoferrin. Ann Clin Lab Sci 45:487-94
Hwang, Shen-An; Kruzel, Marian L; Actor, Jeffrey K (2014) Immunomodulatory effects of recombinant lactoferrin during MRSA infection. Int Immunopharmacol 20:157-63
Zimecki, Micha?; Artym, Jolanta; Koci?ba, Maja et al. (2014) The effect of carbohydrate moiety structure on the immunoregulatory activity of lactoferrin in vitro. Cell Mol Biol Lett 19:284-96
McMullen, Ashley M; Hwang, Shen-An; O'Shea, Kelly et al. (2013) Evidence for a unique species-specific hypersensitive epitope in Mycobacterium tuberculosis derived cord factor. Tuberculosis (Edinb) 93 Suppl:S88-93
Doursout, Marie-Francoise; Horton, Haley; Hoang, Linh et al. (2013) Lactoferrin moderates LPS-induced hypotensive response and gut injury in rats. Int Immunopharmacol 15:227-31
Hwang, Shen-An; Welsh, Kerry J; Boyd, Sydney et al. (2011) Comparing efficacy of BCG/lactoferrin primary vaccination versus booster regimen. Tuberculosis (Edinb) 91 Suppl 1:S90-5
Welsh, Kerry J; Hwang, Shen-An; Boyd, Sydney et al. (2011) Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology. Tuberculosis (Edinb) 91 Suppl 1:S105-13
Hunter, Robert L (2011) On the pathogenesis of post primary tuberculosis: the role of bronchial obstruction in the pathogenesis of cavities. Tuberculosis (Edinb) 91 Suppl 1:S6-10
Kruzel, Marian L; Actor, Jeffrey K; Radak, Zsolt et al. (2010) Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model. Innate Immun 16:67-79

Showing the most recent 10 out of 17 publications